NYSE:JNJ 30 December 2025 - 10 January 2026

Johnson & Johnson shares fell 0.7% on Friday, closing at $204.39. The company said it reached an agreement with the U.S. government to lower drug prices in exchange for exemptions from tariffs.

Johnson & Johnson shares slipped about 0.5% to $204.76 on Friday after the company said it struck an agreement with President Donald Trump’s administration to lower drug prices for Americans in return for exemptions from U.S. tariffs. Johnson & Johnson did not say which medicines are included or how large the price cuts would be.

Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology.

Johnson & Johnson shares eked out a 0.02% gain to $206.95 on Wednesday, a rare green finish as U.S. stocks slipped in the final session of 2025. The S&P 500 fell 0.74% and the Dow lost 0.63%. MarketWatch

Johnson & Johnson shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91.

Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations